ARS Pharmaceuticals Inc Initiation

William Blair initiated research coverage of ARS Pharmaceuticals, Inc. (SPRY $8.50), a clinical-stage biopharmaceutical company focused on developing treatments that are safe, effective, needle-free, easy to carry, and simple to administer for people affected by severe allergic reactions.

Straumann Holding AG Initiation

William Blair initiated research coverage of Straumann Holding AG (STMN-SWX CHF 129.45), a global leader in dentistry with a portfolio of tooth replacement and orthodontic solutions.

Cboe Global Markets Inc Initiation

William Blair initiated research coverage of Cboe Global Markets, Inc. (CBOE $190.84), a leading derivatives and securities exchange network that provides trading, clearing, data, and technology solutions to a broad range of market participants globally.

Elevation Oncology Inc Initiation

William Blair initiated research coverage of Elevation Oncology, Inc. (ELEV $0.56), a clinical-stage biotechnology company advancing a Phase I antibody-drug conjugate (ADC) against claudin 18.2, initially targeting gastric cancer/gastroesophageal junction (GEJ) adenocarcinoma with pancreatic cancer as an expansion opportunity.

Denali Therapeutics Inc Initiation

William Blair initiated research coverage of Denali Therapeutics Inc. (DNLI $20.38), a clinical-stage biotechnology company developing treatments for CNS and other indications by leveraging its unique blood–brain barrier penetrating technology platform.

Affirm Holdings Inc and SoFi Technologies Inc Initations

William Blair initiated research coverage of Affirm Holdings, Inc. (AFRM $54.69) and SoFi Technologies, Inc. (SOFI $14.07), two leaders in digital finance.

Mersana Therapeutics Inc Initiation

William Blair initiated research coverage of Mersana Therapeutics, Inc. (MRSN $0.57), whose lead program emiltatug ledadotin is an ADC that targets B7-H4; it is in Phase I development for TNBC. The company is also developing a HER2-targeted immune-stimulating ADC, XMT-2056, in a Phase I solid tumor study.

How Do We Produce Enough Food for Everyone in a More Crowded and Thirsty World?

William Blair Biotech Equity Research Head Discusses Outlook for COVID-19 Vaccines

Tim Lugo discusses unprecedent efforts of vaccine development.

N-able, Inc. Initiation

William Blair initiated research coverage of N-able, Inc. (NABL $14.22). N-able sells remote monitoring and management (RMM), security and data protection, and business management solutions to managed service providers (MSPs) worldwide.